Clinical trials
Clinical High Risk clinical trials
Below are recruiting clinical high risk clinical trials, each written for real people, not researchers. We’re tracking 567 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07786714Recruiting
Faster brain stimulation for early psychosis risk
This study tests a faster type of brain stimulation, called accelerated neuromodulation therapy, in people who have early signs that could lead to psychosis. The goal is to see if this treatment can help reduce symptoms and improve daily life.
Verdun, QuebecAges 18–34 - NCT05398120Recruiting
Skills group for teens at high risk for psychosis
This study offers a skills-based group program for teens who are considered at high risk of developing a psychotic disorder. It aims to help young people cope and possibly lower the impact of early warning symptoms.
Pittsburgh, PennsylvaniaAges 13–18 - NCT05968560Recruiting
Online therapy to help youth at risk for psychosis
This trial tests a telehealth (video/phone) version of cognitive behavioral therapy to help young people who are at risk for developing psychosis. It may help by teaching skills to reduce symptoms and improve coping, with support from a key family or close person.
New York, New YorkAges 14–25 - NCT06582901Recruiting
Support for youth at clinical high risk for psychosis in Tunisia
This study tests a support program for young people in Tunisia who show early signs of possible psychosis. It aims to help them before more serious symptoms develop.
TunisAges 14–28 - NCT07226895RecruitingPhase 1/Phase 2
Study of MT1988 for people at high risk for psychosis
This trial tests a new drug called MT1988 in people who show early warning signs of psychosis. Researchers want to see if it changes certain markers in the body related to mental health.
Irvine, CaliforniaAges 17–30 - NCT05827549RecruitingPhase 2
Blinatumomab for relapsed ALL, matched by risk group
This Phase 2 study tests how well blinatumomab works for children and adults whose acute lymphoblastic leukemia (ALL) has come back. It also looks at whether results differ based on the patient’s relapse “risk group.”
DaeguAges 1–22 - NCT04047641RecruitingPhase 1/Phase 2
Quizartinib with chemotherapy for new or returning leukemia
This trial tests a combination of anti-leukemia drugs (including quizartinib) together with chemotherapy for people with acute myeloid leukemia (AML), a rare mixed-type leukemia, or high-risk myelodysplastic syndrome (MDS). It may help by trying to better control cancer in people whose disease is newly diagnosed or has returned/not responded to prior treatment.
Houston, TexasAges 18 years+ - NCT05013216RecruitingPhase 1
Vaccine trial for people at high risk of pancreatic cancer
This early-phase trial studies a long-peptide vaccine designed for people with certain genetic changes that raise the risk of pancreatic cancer. The goal is to help your immune system recognize and respond to cancer-related changes before cancer develops.
Baltimore, MarylandAges 40 years+ - NCT06640803Recruiting
Early psychosis risk stepped-care program
This study offers a step-by-step care program for teens and young adults at high risk for psychosis. It aims to provide the right level of support early on to prevent or reduce the severity of symptoms.
Elk Grove, CaliforniaAges 12–25 - NCT06990737RecruitingPhase 2
Sentinel node biopsy for high-risk skin cancer of the head and neck
This trial is testing whether a procedure called sentinel lymph node biopsy (SLNB) can help manage high-risk skin cancer on the head and neck that has not spread to lymph nodes. It is for people whose skin cancer is considered high-risk due to features like size, depth, or location, and who are able to have surgery.
Sacramento, CaliforniaAges 18 years+ - NCT07538635RecruitingPhase 2
CAR-T cells plus stem cell transplant for aggressive lymphoma
This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.
Hangzhou, ZhengjiangAges 18 years+ - NCT06204341Recruiting
Finding the best radiation for high-risk prostate cancer
This trial compares different radiation therapy plans for men with high-risk prostate cancer that has spread to the lymph nodes. It aims to find the best way to treat the prostate and the surrounding lymph nodes while minimizing side effects.
Leidschendam, South HollandAges 18 years+ - NCT07720284RecruitingPhase 3
Testing new drugs for high-risk bladder cancer after surgery
This trial tests a new combination of drugs (Dato-DXd plus rilvegostomig) against standard treatments for people with high-risk, muscle-invasive bladder cancer that has been surgically removed. The goal is to see if the new treatment reduces the chance of the cancer coming back.
Hot Springs, ArkansasAges 18 years+ - NCT06327269RecruitingEarly Phase 1
Targeted therapy after liver transplant for high-risk liver cancer
This trial tests a targeted therapy (lenvatinib) given after a living-donor liver transplant to prevent high-risk liver cancer from coming back. It is for people whose cancer is aggressive or did not respond well to previous treatments.
Kaohsiung CityAges 18–75 - NCT07025369RecruitingPhase 2
Hormone pill before PSMA scan for high-risk prostate cancer
This trial tests if giving a short-term hormone pill (relugolix) before a special PSMA PET/CT scan makes the scan clearer for men with high-risk prostate cancer. It may help doctors better see where the cancer is.
Scottsdale, ArizonaAges 18 years+ - NCT07301866RecruitingPhase 1/Phase 2
Testing an improved dose of UM171 for cord blood transplant
This trial tests a higher dose of UM171 to make cord blood transplants safer and more effective for people with certain blood cancers or bone marrow diseases. It aims to help patients who don't have a suitable donor.
Montreal, QuebecAges 18–67 - NCT00291096Recruiting
Clinic program for women at high risk of breast cancer
This trial enrolls women who are at higher-than-usual risk of developing breast cancer to help guide prevention and monitoring. You may be asked to get a recent mammogram, have blood tests, and follow medication/supplement changes.
Kansas City, KansasAges 30–65 - NCT07549321RecruitingPhase 2/Phase 3
Hu14 Immunotherapy for High-Risk Neuroblastoma in Children
This study tests a new antibody-based immunotherapy called hu14 for children and young adults with high-risk neuroblastoma (an aggressive childhood cancer that has spread). The treatment is designed to help the immune system fight cancer cells.
Aurora, ColoradoAges 1.5 years–18 years - NCT07284485RecruitingPhase 2
Preventing lung cancer in people with high-risk lung spots
This trial tests an immunotherapy approach to stop high-risk lung spots from turning into cancer. It is for people who are current or former heavy smokers with multiple slow-growing lung nodules that are not yet ready for surgery.
New York, New YorkAges 18 years+ - NCT06488482RecruitingPhase 3
Short immunotherapy after melanoma surgery
This trial tests whether giving a shorter course of immunotherapy after surgery can help prevent melanoma from coming back. It is for people with high-risk melanoma who have had the cancer fully removed.
HelsinkiAges 18 years+ - NCT06745687Recruiting
BCMA/CD3 antibody for high-risk smoldering myeloma
This trial tests a new medicine called a BCMA/CD3 bispecific antibody for people with a very early form of multiple myeloma called high-risk smoldering myeloma. The goal is to see if this treatment can stop the disease from getting worse.
TianjinAges 18–78 - NCT03383575RecruitingPhase 2
Azacitidine plus enasidenib for IDH2-mutant MDS
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
Baltimore, MarylandAges 12 years+ - NCT06098235Recruiting
Test of the Oriental diet for brain health in people at high stroke risk
This trial tests whether a special diet (the Oriental diet) can help protect thinking and memory in people who have several stroke risk factors. It may be a good fit if you are 40 or older and have three or more stroke risk factors, such as high blood pressure, diabetes, or being overweight.
Hangzhou, ZhejiangAges 40 years+ - NCT06625970RecruitingPhase 3
Darolutamide and high-dose radiation for high-risk prostate cancer
This trial tests a combination of a hormone therapy pill (darolutamide) and a high-dose, precise form of radiation for men with localized prostate cancer that has high-risk features of coming back. The goal is to see if this approach is more effective than standard treatment.
BrestAges 18–80
Hear when a new Clinical High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical high risk?
- Yes. Clin2 currently lists 567 recruiting clinical high risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical high risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical high risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.